Cyclosporin A in the treatment of cutaneous vasculitis. Clinical and cellular effects

Journal of the European Academy of Dermatology and Venereology

Volumn 6, Issue 2, 1996, Pages 135-141

  Tosca, A D ^a,c   Ioannidou, D J ^a   Katsantonis, J C ^a   Kyriakis, K P ^b  

^a UNIVERSITY OF CRETE   (Greece)

^b Western Attica General Hospital   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Adhesion molecules; Cutaneous vasculitis; Cyclosporin A; Immunohistochemistry

Indexed keywords

CYCLOSPORIN A; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; PREDNISOLONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VASCULITIS;

EID: 0030007285     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/0926-9959(94)00000-X     Document Type: Article

References (38)

1. Tosca N, Stratigos JD. Possible pathogenetic mechanisms in allergic cutaneous vasculitis. Int J Dermatol 1988;27:291-296.
2. Tosca AD, Stratigos JD. Immulogic mechanisms in allergic cutaneous vasculitis: cellular interactions, effects of cytokines, therapeutic insights. J Eur Acad Dermatol Venereol 1992;1:176-186.
3. Osborn L. Leukocyte adhesion to endothelium and inflammation Cell 1990;82:3-6
4. Diamond MS, Staunton DE, Marlin SD, et al. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 1991;65:961-971.
5. Butcher EC. Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity. Cell 1991;67:1033-1036.
6. Hynes RO, Lauder AD. Contact and adhesive specificities in the associations, migrations and targeting of cells and axons. Cell 1992;68:303-322.
7. Nathan C, Srimal S, Farber C, et al. Cytokine-induced respiratory burst of human neuthophils:dependence on extracellular matrix proteins and CD11/CD18 integrins. J Cell Biol 1989;109:1341-1349.
8. Shimizu Y, Van Seventer GA, Morgan KJ, et al. Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol 1990;145:59-67.
9. Sporn SA, Eierman DF, Johnson CE, et al. Monocyte adherence results in selective induction of novel genes sharing homology with mediators of inflammation and tissue repair. J Immunol 1990;144:4434-4441.
10. Burkly LC, Jakubowski A, Newman BM, et al. Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD-3 dependent T-cell proliferation Eur J Immunol 1991;21:2871-2875.
11. Ruoslahti E. Integrins. J Clin Invest 1991;87:1-5
12. Dustin ML, Springer TA. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Am Rev Immunol 1991;9:2-66.
13. Ho VC, Lui H, McLean D.I. Cyclosporine in nonpsoriatic dermatoses. J Am Acad Dermatol 1990;23:1248-59.
14. Gupta AK, Brown MD, Ellis CN, et al. Cyclosporine in dermatology. J Am Acad Dermatol 1989;21:1245-1256.
15. Schaumburg-Lever G. Immunoenzyme techniques in dermatopathology. Int J Dermatol 1986;25:217-223.
16. Tosca N: Immunological mechanisms in cutaneous vasculitis;in Dermatology in Europe. Proceedings of the 1st Congess of the European Academy of Dermatology and Venereology, Florence, Italy, 25-28 September, 1989 in Panconesi E (ed): Blackwell Scientific publications pp 324-328.
17. Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL-1 and interferon gamma: tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986;137:245-254.
18. Ho VC, Griffiths CEM, Ellis CN, et al. Intralesional cyclosporine in the treatment of psoriasis. J Am Acad Dermatol 1990;22:95-99.
19. Petzelbauer P, Stingl G, Wolff K, et al. Cyclosporine A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J Invest Dermatol 1991;96:362-369.
20. Burridge K, Fath K. Focal contacts: transmebrane links between the extracellular matrix and the cytockeleton. Bio Essays 1989;10:104-108.
21. r-src. Oncogene 1989;4:325-333.
22. Otey CA, Pavalko FM, Burridge K. An interaction between a-actinin and the b1 integrin subunit in vitro. J Cell Biol 1990;11:721-729.
23. Hynes RO. Integrins: Versatility, modulation and signaling in cell adhesion. Cell 1992;69:11-25.
24. Van Kooyk Y, van de Wief-van Kamenade P, Weder P, et al. Enhacement of LFA-1 mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes. Nature 1989;342:811-813.
25. Isakov N, Mally MI, Scholz W, et al. T-lymphocyte activation: the role of protein kinase C and the bifurcating inositol phospholipid signal trasduction pathway. Immunol Rev 1987;95:89-111.
26. Gupta AK, Baadsgaard O, Ellis CN, et al.Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A. Arch Dermatol Res 1989;281:219-226.
27. Cooper KD, Voorhees JJ, Fisher GJ, et al. Effects of cyclosporine on immunologic mechanisms in psoriasis. J Am Acad Dermatol 1990;23:1318-1328.
28. Moss ML, Palmer RE, Kuzmic P, et al. Identification of actin and HSP 70 as cyclosporin A binding proteins by photoaffinity labeling and fluorescence displacement assays. J Biol Chem 1992;267:22054-22059.
29. Kolansky G, Griffiths CEM and Voorhees JJ. Cyclosporine: uses and mechanism of actin in skin disease In Dermatology, Progress and Perspectives. The proceedings of the 18th World Congress of Dermatology, Burgdof WHC and Katz SI (eds). New York, June 12-18, 1992. The Parthenon Publishing Group, pp 1018-1022.
30. Mozzanica N, Pigatto PD, Finzi AF. Cyclosporin in psoriasis: Pathophysiology and Experimental Data. Dermatology 1993;187 (suppl 1) 3-7.
31. Griffiths CEM, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989;20:617-629.
32. Gottlieb AB, Grossman RM, Khandke L, et al. Studies of the effect of Cyclosporine in Psoriasis in vivo: combined effects on activated T- lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992;98:302-309.
33. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992;126:1-9.
34. Barker JN, Markey AC, Allen MH, et al. Keratinocyte expression of OKM5 antigen in inflammatory cutaneous disease. Br J Dermatol 1989;120:613-618.
35. Horrocks C, Ormerod AD, Duncan JI, et al. Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions. Clin Exp Immunol 1989;78:166-171.
36. Jennette CJ, Milling DM, Falk RJ. Vasculitis affecting the skin. A Review. Arch Dermatol 1994;130:899-906.
37. Schollmeyer P, GrotzW. Ciclosporin in the treatment of Wegener's granulomatosis (WG) and related diseases. APMIS 1990, Suppl. 19;98:54-55.
38. Mizushima Y. Behcet's disease. Current Opinion in Rhematology 1991;3:32-35.